PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.
|Acute Myeloid Leukemia (AML)||Drug: cytarabine Drug: daunorubicin hydrochloride Drug: midostaurin||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytarabine for Consolidation in Patients With Acute Myeloid Leukemia (AML)|
- Complete Response (CR) rate [ Time Frame: cycle 1, day 14, cycle day 21 - 28, end of each cycle ]cycle = between 28 days and 42 days in duration
- CR rate by FLT3 mutation and treatment arm [ Time Frame: CR:cycle 1, day 14, cycle day 21 - 28, end of each cycle, FLT3: monthly ]
- Overall survival by FLT3 mutation status [ Time Frame: time of death of any cause(FLT# - minthly) ]
|Study Start Date:||February 2004|
|Study Completion Date:||June 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
Experimental: PKC412 administered sequentially
twice daily oral dosing of PKC412 administered sequentially
Other Name: PKC412
Experimental: PKC412 administered concomitantly
PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
Drug: daunorubicin hydrochloride
Other Name: PKC412
- Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia.
- Compare the pharmacokinetics of these regimens in these patients.
- Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients.
- Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens.
OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups.
- Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity.
- Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity.
In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy.
- Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00093600
|United States, California|
|Jonsson Comprehensive Cancer Center at UCLA|
|Los Angeles, California, United States, 90095-1781|
|United States, Massachusetts|
|Dana Faber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|United States, Michigan|
|Wayne State University/Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-2014|
|United States, Texas|
|MD Anderson Cancer Center/University of Texas|
|Houston, Texas, United States, 77030|
|Novartis Investigative Site|
|Novartis Investigative Site|
|Study Director:||Novartis Investigative Site, MD||Novartis Investigative Site|